DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > Graduate School of Biomedical Sciences > Articles in academic journal >

Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis


File Description SizeFormat
IntMed49_2211.pdf395.78 kBAdobe PDFView/Open

Title: Efficacy and Safety of Mizoribine by One Single Dose Administration for Patients with Rheumatoid Arthritis
Authors: Ichinose, Kunihiro / Origuchi, Tomoki / Kawashiri, Shin-ya / Iwamoto, Naoki / Fujikawa, Keita / Aramaki, Toshiyuki / Kamachi, Makoto / Arima, Kazuhiko / Tamai, Mami / Nakamura, Hideki / Ida, Hiroaki / Kawakami, Atsushi / Tsukada, Toshiaki / Ueki, Yukitaka / Eguchi, Katsumi
Issue Date: 2010
Publisher: The Japanese Society of Internal Medicine / 日本内科学会
Citation: Internal Medicine, 49(20), pp.2211-2218; 2010
Abstract: Objective Mizoribine (MZR) is an immunosuppressant that inhibits nucleic acid metabolism and is a relatively safe disease-modifying anti-rheumatic drug (DMARD). We evaluated the efficacy and safety of one single dose per day for patients with rheumatoid arthritis (RA). Patients and Methods In this study 32 patients with RA received MZR therapy. We evaluated the average dose of MZR and prednisolone, response to treatment and peak plasma level of MZR. Results The average dose of MZR was 146.1±31.2 (range: 50-200) mg/day. The average dose of prednisolone was 4.63±3.59 (range: 0-14) mg/day. The average plasma level of MZR, measured after 3 hours, was 2.20±0.49 μg/mL in the responder group and 1.59±0.82 μg/mL in the non-responder group (p=0.020). The treatment with MZR for 24 weeks was completed by 71.9% of patients and the proportion of patients who achieved a good and moderate response rate according to the European League Against Rheumatism (EULAR) criteria was 56.3% at 24 weeks. The plasma level of MZR which was greater than or equal to 2.12 μg/ mL was significantly correlated with the clinical response (p<0.01). Only one of thirty-two cases discontinued the treatment, because of skin eruption. Conclusion This study included patients that could not be treated with other DMARDs and/or biologic agents because of age, interstitial pneumonia and other complications. We show that MZR may be a useful and relatively safe therapy for patients in this group.
Keywords: Mizoribine (MZR) / Plasma level / Rheumatoid arthritis (RA)
URI: http://hdl.handle.net/10069/24559
ISSN: 09182918
DOI: 10.2169/internalmedicine.49.3810
Rights: Copyright (c) 2010 by The Japanese Society of Internal Medicine
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/24559

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace